|
NEWS CENTER
DOR
BioPharma 2004 News Archive.
Dec 30 , 2004
DOR
BioPharma, Inc. Announces Top-Line Results of Pivotal
Phase III Clinical Trial of orBec® for Intestinal Graft-versus-Host
Disease
Dec
10 , 2004
DOR
BioPharma Appoints Michael T. Sember as President and
Chief Executive Officer. Former Acting CEO Evan Myrianthopoulos
Appointed Chief Financial Officer.
Dec
6, 2004
DOR
BioPharma to submit compliance plan to AMEX
Nov
30 , 2004
DOR’
s Ricin Vaccine (RiVax™) to Enter Human Clinical Trials
Nov
17, 2004
DOR
to Present Live Webcast at New York Society of Security
Analysts’ 8th Annual Heathcare Conference, Tomorrow,
Nov. 17, 2004, 3:10pm ET
Nov
11 , 2004
DOR
BioPharma announces the appointment of Alexander P.
Haig as Chairman of the board.
Oct
15 , 2004
DOR
BioPharma Appoints James Clavijo, C.P.A., M.A. Controller,
Treasurer and Corporate Secretary
Sep
21, 2004
DOR
BioPharma to Participate in BioDefense Briefing at the
National Press Club
Sep
15, 2004
DOR
BioPharma Announces the Completion of the Pivotal Phase
III Clinical Trial of orBec®
Sep
13, 2004
DOR
Biopharma receives $5.2 million from National Institutes
of Health for continued development of Ricin Vaccine
Sep
10, 2004
DOR
BioPharma to Present at Equities Magazine Discovery
Day XI Conference
Aug
16, 2004
DOR
BioPharma, Inc. Announces Stock Repurchase Program
Aug
13 , 2004
DOR
BioPharma, Inc. Announces Second Quarter 2004 Financial
Results and Achievements
Aug
3, 2004
DOR
BioPharma to Present at Upcoming Southern California
Investment Association Conference
Jul
26, 2004
DOR
BioPharma Provides Update on BioDefense Programs Company
Hosts Webcast on New Corporate Website WWW.DORBIOPHARMA.COM
Jul
21, 2004
DOR
BioPharma Announces Webcast to Discuss Impact of Enactment
of Project Bioshield Act of 2004
Jul
14, 2004
DOR
BioPharma, Inc. Completes Enrollment in Pivotal Phase
III Clinical Trial of orBec for Acute Intestinal Graft-versus-Host
Disease
Jul
9, 2004
DOR
BioPharma Announces Management Changes
Jun
16, 2004
DOR
BioPharma and Thomas Jefferson University Collaborate
With U.S. Army to Advance Development of Botulinum Toxin
Vaccines.
Apr
14, 2004
DOR
BioPharma Announces Annual Meeting Date
Mar
31 , 2004
DOR
BioPharma Reports Fourth Quarter and Year End Financial
Results and Accomplishments for 2003
Mar
15 , 2004
DOR
BioPharma Closes $3.25 Million Private Placement
Mar
4, 2004
DDOR
BioPharma, Inc. Announces Private Equity Financing of
$3.25 Million
Mar
4, 2004
DOR
Announces Conversion of All Outstanding Preferred Stock
into Common Stock
Feb
12, 2004
DOR
BioPharma, Inc. Announces Appointment of Dr. James S.
Kuo and Stuart D. Sedlack to its Board of Directors
Feb
4, 2004
DOR
BioPharma, Inc. Provides Update on Ricin Vaccine Development
Program
|
